Antibody Humanization Technologies

The first monoclonal antibodies were typically made entirely from mouse cells. One problem with this is that the human immune system will see these antibodies as foreign (because they’re from a different species) and will mount a response against them. In the short term, this can sometimes cause an immune response. In the long term, it means that the antibodies may only work the first time they are given; after that, the body’s immune system is primed to destroy them before they can provide treatment. This study presents a technology that generates stable, soluble, ultra-humanized antibodies via single-step CDR redundancy minimization. Lead clones demonstrated high stability, with affinity and specificity equivalent to, or better than, the parental immunoglobulin. This significantly lowered non-human sequence content, minimized t- and b-cell epitope risk in the final molecules and provided a heat map for the essential non-human CDR residue content of antibodies from disparate sources. Antibody humanization uses multiple sequence segments derived from variable (V) regions of unrelated human antibodies, unlike other technologies that typically use a single human V region framework as acceptors for complementarity determining regions (CDRs) from starting antibodies (typically rodent). Through careful selection of human sequence segments and the application of in silico tools, CD4+ T cell epitopes are avoided so the risk of immunogenicity is reduced compared to standard humanized antibodies whilst antibody affinity and specificity is maintained. Immunogenicity assessment technology is used to confirm T cell epitopes have been removed.

  • Rapid Humanization and Affinity Improvement of a Murine Antibody
  • IMGT Databases and Tools for Antibody Engineering and Humanization
  • Immunogenicity Assessment Strategies to Support the Development of Biological Therapeutics
  • Therapeutic Antibody Discovery and Development Using Humanized RabMAbs
  • Humanized Antibodies and Their Therapeutic Value
  • Non-human Primate Immune Libraries Combined with Germline Humanization
  • A Novel Fully Human Monoclonal Antibody Platform Using Transgenic Rats

Related Conference of Antibody Humanization Technologies

June 29-July 01, 2017

8th European Immunology Conference

Madrid, Spain
July 03-04, 2017

9th Annual Meeting on Immunology and Immunologist

Kuala Lumpur, Malaysia
July 12-13, 2017

3rd World Conference on Parasitology & Pathogenesis

Chicago, Illinois, USA
September 01-02, 2017

4th International Conference on Parasitology

Prague, Czech Republic
September 14-15, 2017

7th World Congress on Immunology

Amsterdam, Netherlands
September 21-22, 2017

International Conference on Parasitology and Infectious Diseases

San Antonio, Texas, USA
November 01-03, 2017

Vaccines-2017 (CME & CPD Accredited)

Valencia, Spain
November 06-08, 2017

Infectious-diseases- 2017 (CME & CPD Accredited)

Valencia, Spain
November 2-3, 2017

9th World Congress and Expo on Immunology

Atlanta, Georgia, USA
November 02-03, 2017

9th World Congress on Immunity, Inflammation and Immunotherapies

Atlanta, Georgia, USA
November 06-07, 2017

2nd International Conference on Autoimmunity

Frankfurt, Germany
November 06 - 07, 2017

Immunology-2017

Frankfurt, Germany
November 08-09, 2017

3rd Antibodies and Bio Therapeutics Congress

Las Vegas, Nevada, USA
November 13-14, 2017

5th International Conference on HIV/AIDS, STDs and STIs

Las Vegas, Nevada, USA
December 04-06, 2017

Oncology- 2017 (CME & CPD Accredited)

London, UK
Dec 14-15, 2017

World Immunology Congress

Dubai, UAE

Antibody Humanization Technologies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in